- Home
- RLTY vs NERV Comparison
RLTY vs NERV Comparison
Compare RLTY & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | NERV |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 269.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RLTY | NERV |
|---|---|---|
| Price | $15.91 | $6.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 84.9K | ★ 103.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 104.12 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.90 | $1.15 |
| 52 Week High | $16.25 | $12.46 |
Technical Indicators
Market Signals| Indicator | RLTY | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 71.88 |
| Support Level | $14.95 | $5.66 |
| Resistance Level | N/A | $6.69 |
| Average True Range (ATR) | 0.23 | 0.56 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 91.11 | 93.69 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.